Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, particularly through its lead product candidate, atebimetinib, which targets various cancer indications [1][3]. Group 1: Company Overview - Immuneering Corporation is dedicated to keeping cancer patients alive and helping them thrive by developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral, once-daily medication designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [3]. - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]. Group 2: Upcoming Events - Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, discussing the company's pipeline, platform, and business strategy [1]. - The presentation is scheduled for February 26, 2026, at 10:00 am ET and will be available via live webcast and archived on the company's Investor Relations website [2].